229 related articles for article (PubMed ID: 37404982)
1. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors.
Rashmi P; Sigdel TK; Rychkov D; Damm I; Da Silva AA; Vincenti F; Lourenco AL; Craik CS; Reiser J; Sarwal MM
Ann Transl Med; 2023 Jun; 11(9):315. PubMed ID: 37404982
[TBL] [Abstract][Full Text] [Related]
2. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation.
Delville M; Sigdel TK; Wei C; Li J; Hsieh SC; Fornoni A; Burke GW; Bruneval P; Naesens M; Jackson A; Alachkar N; Canaud G; Legendre C; Anglicheau D; Reiser J; Sarwal MM
Sci Transl Med; 2014 Oct; 6(256):256ra136. PubMed ID: 25273097
[TBL] [Abstract][Full Text] [Related]
3. Update on Recurrent Focal Segmental Glomerulosclerosis in Kidney Transplantation.
Shoji J; Mii A; Terasaki M; Shimizu A
Nephron; 2020; 144 Suppl 1():65-70. PubMed ID: 33260184
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
5. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
6. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
Beaudreuil S; Zhang X; Kriaa F; Dantal J; Francois H; Vazquez A; Charpentier B; Lorenzo HK; Durrbach A
Nephrol Dial Transplant; 2014 Feb; 29(2):458-63. PubMed ID: 24235085
[TBL] [Abstract][Full Text] [Related]
7. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.
Otalora L; Chavez E; Watford D; Tueros L; Correa M; Nair V; Ruiz P; Wahl P; Eddy S; Martini S; Kretzler M; Burke GW; Fornoni A; Merscher S
PLoS One; 2019; 14(10):e0222948. PubMed ID: 31581251
[TBL] [Abstract][Full Text] [Related]
8. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
9. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.
Wada T; Nangaku M
Clin Kidney J; 2015 Dec; 8(6):708-15. PubMed ID: 26613029
[TBL] [Abstract][Full Text] [Related]
10. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Kim EY; Roshanravan H; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
[TBL] [Abstract][Full Text] [Related]
11. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
12. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
13. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
14. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
BMC Med; 2014 May; 12():81. PubMed ID: 24884842
[TBL] [Abstract][Full Text] [Related]
15. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.
Kachurina N; Chung CF; Benderoff E; Babayeva S; Bitzan M; Goodyer P; Kitzler T; Matar D; Cybulsky AV; Alachkar N; Torban E
Am J Physiol Renal Physiol; 2016 May; 310(10):F1148-56. PubMed ID: 26719363
[TBL] [Abstract][Full Text] [Related]
16. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
[TBL] [Abstract][Full Text] [Related]
17. Serum suPAR in patients with FSGS: trash or treasure?
Maas RJ; Deegens JK; Wetzels JF
Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Rituximab in Treatment-Resistant Focal Segmental Glomerulosclerosis With Elevated Soluble Urokinase-Type Plasminogen Activator Receptor and Activation of Podocyte β3 Integrin.
Hladunewich MA; Cattran D; Sethi SM; Hayek SS; Li J; Wei C; Mullin SI; Reich HN; Reiser J; Fervenza FC
Kidney Int Rep; 2022 Jan; 7(1):68-77. PubMed ID: 35005315
[TBL] [Abstract][Full Text] [Related]
19. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
Kronbichler A; Saleem MA; Meijers B; Shin JI
J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
[TBL] [Abstract][Full Text] [Related]
20. Integrated genomic, transcriptomic and metabolomic analysis reveals MDH2 mutation-induced metabolic disorder in recurrent focal segmental glomerulosclerosis.
Shen Q; Teng L; Wang Y; Guo L; Xu F; Huang H; Xie W; Zhou Q; Chen Y; Wang J; Mao Y; Chen J; Jiang H
Front Immunol; 2022; 13():962986. PubMed ID: 36159820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
